Viking Therapeutics, Inc. - Common Stock (VKTX)
32.68
+0.11 (0.34%)
NASDAQ · Last Trade: Aug 3rd, 11:54 AM EDT
Detailed Quote
Previous Close | 32.57 |
---|---|
Open | 32.00 |
Bid | 32.40 |
Ask | 32.70 |
Day's Range | 31.80 - 33.57 |
52 Week Range | 18.92 - 81.73 |
Volume | 3,354,968 |
Market Cap | 3.25B |
PE Ratio (TTM) | -21.36 |
EPS (TTM) | -1.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,880,834 |
Chart
About Viking Therapeutics, Inc. - Common Stock (VKTX)
Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More
News & Press Releases
These biotech businesses look compelling for very different reasons.
Via The Motley Fool · August 3, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · July 26, 2025
Via Benzinga · July 24, 2025
Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter.
Via Benzinga · July 23, 2025
Via Benzinga · July 23, 2025
Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.
Via Chartmill · July 23, 2025
Via The Motley Fool · July 20, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via The Motley Fool · July 19, 2025
Via The Motley Fool · July 4, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via MarketBeat · June 29, 2025